MCWG

Microscopic colitis (MC) has long been one of the most common yet under-recognised causes of chronic diarrhoea. Although many patients achieve symptom control with budesonide, a substantial subgroup develops refractory, dependent or intolerant disease, creating significant therapeutic challenges for both patients and clinicians. Despite these unmet needs, evidence to guide treatment beyond budesonide has remained remarkably limited.

We are pleased to announce the establishment of the Working Group on Microscopic Colitis (MCWG) at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO) in Stockholm. This represents a significant step forward in strengthening research, collaboration and clinical guidance in this important field of Inflammatory Bowel Diseases (IBDs).